A Ring Or Polycyclo Ring System In A Substituent E Is Attached Indirectly To The Carboxamide Nitrogen Or To An Amino Nitrogen In Substituent E By Acyclic Nonionic Bonding Patents (Class 514/630)
  • Patent number: 9402854
    Abstract: The present invention relates to a pharmaceutical composition comprising arformoterol and fluticasone furoate (preferably for once daily administration), to a process for preparing such a composition and to the use of such a composition for the treatment and/or prevention of respiratory, inflammatory or obstructive airway disease.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: August 2, 2016
    Assignee: Cipla Limited
    Inventors: Shrinivas Purandare, Geena Madhukar Malhotra
  • Patent number: 9320724
    Abstract: A method of improving cognition in a patient with Down syndrome, which entails administering one or more ?2 adrenergic receptor agonists to the patient in an amount and with a frequency effective to improve cognition of the patient as measured by contextual learning tests.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: April 26, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Ahmad Salehi, Brian Mediana, Sarah Moghadam, Van Dang, Devsmita Das, Kara Martin
  • Patent number: 9220708
    Abstract: This invention provides a pharmaceutical composition comprising a eutectic composition of two pharmacologically active ingredients for delivery to the lung by inhalation. This invention also provides a pharmaceutical composition comprising a eutectic composition of two pharmacologically active ingredients for the treatment of respiratory disease.
    Type: Grant
    Filed: August 8, 2012
    Date of Patent: December 29, 2015
    Assignee: Prosonix Limited
    Inventors: Graham Ruecroft, Dipesh Parikh
  • Patent number: 9072704
    Abstract: A new use for paracetamol in a method of treating glaucoma, which method comprises administering to a patient in need of such treatment 500 mg to 1000 mg of paracetamol in oral format 4 to 6 hourly. An ophthalmic solution is also provided containing between 0.1 to 5% of paracetamol which is administered as one to two drops in each eye 4 to 6 hourly. The ophthalmic solution further includes one or more of the following excipients: hydroxypropylmethylcellulose, benzalconium chloride, polyacrylic acid such as Teargel®.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: July 7, 2015
    Assignee: Stellenbosch University
    Inventor: David Meyer
  • Publication number: 20150148379
    Abstract: The present invention relates to an acetaminophen injectable aqueous solution for use in the treatment or in the prevention of pain by spinal administration, wherein said acetaminophen injectable solution is supersaturated. In certain embodiments, the acetaminophen injectable aqueous solution is administered simultaneously, separately or sequentially with a local anaesthetic by spinal administration.
    Type: Application
    Filed: June 27, 2013
    Publication date: May 28, 2015
    Inventors: Augusto Mitidieri, Elisabetta Donati, Nicola Caronzolo
  • Publication number: 20150148419
    Abstract: Isolated metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]-methyl]propanamide, methods for their use, and compositions containing the metabolites.
    Type: Application
    Filed: May 17, 2013
    Publication date: May 28, 2015
    Inventors: Marlene Michelle Dressman, Deepak Phadke
  • Patent number: 9040588
    Abstract: The compound of formula (I) is a water-stable, long acting ?2-selective adrenoceptor agonist useful as a bronchodilator in the treatment of bronchoconstriction associated with reversible obstructive airways diseases and the like. Processes for making the compound of formula (I), as well as related intermediates, are disclosed.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: May 26, 2015
    Assignee: SUNOVION PHARMACEUTICALS INC.
    Inventors: Craig R. Abolin, H. Scott Wilkinson, Paul McGlynn, William K. McVicar
  • Publication number: 20150140113
    Abstract: The present invention generally relates to dosage forms for oral administration including one or more gelling agents. In particular, the present invention is directed to gelling agent-based dosage forms that are easily administered and taken, or swallowed. The present invention is also directed to gelling agent-based dosage forms that exhibit relatively low syneresis, are thermally stable, exhibit substantially constant active ingredient concentration, and/or exhibit one or more advantageous rheological properties. In particular, the present invention is directed to such gels containing one or more omega-3 fatty acids. The gelling agent-based dosage forms of the present invention are suitable for administration of a relatively large dose of active ingredient. The gelling agent-based dosage forms of the present invention are also suitable for administration of multiple active ingredients.
    Type: Application
    Filed: March 19, 2013
    Publication date: May 21, 2015
    Applicant: PARTICLE DYNAMICS INTERNATIONAL, LLC
    Inventors: Irwin Jacobs, Stephen Gee, Paul Brady
  • Publication number: 20150141519
    Abstract: The present invention relates to an Agomelatine sulfuric acid complex in formula (I) and the preparation method thereof (HX=H2SO4, RSO3H (R=CH3, Ph, 4-CH3Ph)). The solubility of the Agomelatine sulfuric acid complex obtained by the method of the present invention is significantly improved compared with Agomelatine, has good stability and higher purity, and is suitable for application in finished-product medicinal preparations. The preparation process is quite simple, and a product with high purity can be obtained without special operations.
    Type: Application
    Filed: May 14, 2013
    Publication date: May 21, 2015
    Inventors: Haiping Wang, Cheng Chi, Zhengming Chi, Jin Wang, Guanyu Xu
  • Patent number: 9029420
    Abstract: Agomelatine crystal, which is a drug for treating depression, and pharmaceutical compositions thereof are provided. The X-ray powder diffraction spectra of such agomelatine crystal, which is irradiated by Cu-K? and showed by 2?(degree), has characteristic diffraction peaks at 12.84, 13.84, 16.14, 18.56, 19.12, 20.86, 21.20, 23.84; its IR absorption pattern has characteristic absorption peaks at about 3234, 3060, 2940, 1638, 1511, 1436, 1249, 1215, 1184, 1032, 908, 828, 755, 588 cm-1, and its DSC endothermic transition temperature is 97.6° C. The use of the agomelatine crystal as an active ingredient in preparing a medicament for the treatment of depression is also provided.
    Type: Grant
    Filed: December 13, 2010
    Date of Patent: May 12, 2015
    Assignee: Tianjin Taipu Pharmaceutical Science & Technology Development Co., Ltd.
    Inventors: Jianqiang Zhu, Qingson Tian, Jian Zhao
  • Publication number: 20150118303
    Abstract: Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.
    Type: Application
    Filed: November 12, 2014
    Publication date: April 30, 2015
    Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Manuel A. Vega Zepeda
  • Patent number: 9018193
    Abstract: Novel water stable pharmaceutical compositions, their liquid form oral pharmaceutical compositions and kits thereof, rehydration beverages containing these water stable pharmaceutical compositions methods of manufacture and methods of use thereof are disclosed. The novel aqueous delivery systems are useful, inter alia, as alternative pharmaceutical dosing agents to tablets, capsules and other forms of delivering medication to a mammalian host in need thereof.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: April 28, 2015
    Assignee: Bev-Rx, Inc.
    Inventor: Kyle A. Reed
  • Publication number: 20150105471
    Abstract: The invention relates to an aqueous pharmaceutical composition, preferably an infusion solution, for parenteral administration which contains paracetamol and has an electrical conductivity of not more than 200 ?S cm?1. The invention relates to an aqueous pharmaceutical composition, preferably an infusion solution, for parenteral administration which contains paracetamol and has an electrical conductivity of not more than 200 ?S cm?1.
    Type: Application
    Filed: May 20, 2014
    Publication date: April 16, 2015
    Applicant: Fresenius Kabi Deutschland GmbH
    Inventors: David Dasberg, Georg Achleitner, Christiane Aichholzer
  • Publication number: 20150087649
    Abstract: Methods and agents are provided for treatment of disorders associated with aberrant adrenocortical cell behavior, including (but not limited to) treatment of adrenocortical carcinoma (ACC) and/or Cushing's syndrome. Such methods involve administration of an agent which exhibits an IC50 value against huACAT1 of less than 10 ?M, and one or more further characteristics including effects on adrenocortical cells, disruption of cholesterol homeostasis, reduction in steroid biosynthesis, reduction of mitochondrial function, and/or preferential binding to by low-density lipoprotein (LDL).
    Type: Application
    Filed: September 26, 2014
    Publication date: March 26, 2015
    Inventors: Stephen Warren Hunt, III, Julia Christine Owens, William E. Rainey, JR., Christopher R. LaPensee, Gary D. Hammer
  • Patent number: 8974831
    Abstract: Carrier particles in which at least 60% of the surface is coated with magnesium stearate are useful for preparing dry powder formulations for inhalation.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: March 10, 2015
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Rossella Musa, Daniela Cocconi, Alain Chamayou, Laurence Galet
  • Patent number: 8969416
    Abstract: A pharmaceutical formulation contains 10-60% by weight acetaminophen as the only active ingredient and a solvent system for dissolving the acetaminophen. The formulation is free of any ionizing agent and its solvent system includes water, polyethylene glycol, and polyvinylpyrrolidone that is 2-50% by weight and has a molecular weight of 2,000 to 1,500,000. Also disclosed is another acetaminophen formulation containing polyvinylpyrrolidone as high as 25-50% by weight.
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: March 3, 2015
    Assignee: Enspire Group LLC
    Inventors: Abdul Rashid, Zhang Julia Zhang, Minh Tran, Dahai Guo
  • Patent number: 8962601
    Abstract: This invention relates to pharmaceutical products and compositions for use in the treatment of asthma and related disorders, and especially but not exclusively for the treatment of chronic obstructive pulmonary disease (COPD). More particularly, the invention provides pharmaceutical products and compositions comprising specific anticholinergic agents, ?-2 agonists and corticosteroids.
    Type: Grant
    Filed: August 29, 2003
    Date of Patent: February 24, 2015
    Assignee: Cipla Ltd
    Inventors: Amar Lulla, Geena Malhotra
  • Publication number: 20150045396
    Abstract: The present invention provides a prophylactic or therapeutic agent for giant cell tumors occurring in a bone and soft tissue or for chondrosarcoma, which comprises a non-steroidal anti-inflammatory agent or thiazolidine derivative as an active ingredient, and the like
    Type: Application
    Filed: March 18, 2013
    Publication date: February 12, 2015
    Applicant: NIPPON CHEMIPHAR CO., LTD.
    Inventors: Akihiko Takeuchi, Hiroyuki Tsuchiya
  • Publication number: 20150045442
    Abstract: Novel melatonin ligands of Formula I: or pharmaceutically acceptable salts thereof wherein: n is 1 or 2; m is 0, 1 or 2; p is 0, 1, 2, 3, 4, 5, 6, 7 or 8; v is 2 or 3; A is aryl or heteroaryl; Z is O, S or NR8; Y is selected from the group consisting of hydrogen, aryl, heteroaryl, C1-C6 alkyl, C3-C6 cycloalkyl, and R is selected from the group consisting of hydrogen, hydroxyl, —OCF3, CF3, C1-C8 alkyl, C1-C8 alkyloxy, C1-C8 alkylthio, halogen and —Z—(CH2)p-A; R1 is selected from the group consisting of C1-C4 alkyl, C3-C6 cycloalkyl, CF3, hydroxy-substituted C1-C4 alkyl, hydroxy-substituted C3-C6 cycloalkyl, and NHR5, wherein R5 is C1-C3 alkyl or C3-C6 cycloalkyl; R2 is selected from the group consisting of: hydrogen, C1-C4 alkyl, C1-C4 alkyloxy, OCF3, CF3, hydroxyl, and halogen; R3 is selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 alkyloxy, OCF3, CF3, hydroxyl, and halogen; R and R3 may be connected together to form an —O—(CH2)v bridge representing with the carbon atoms to which the
    Type: Application
    Filed: June 13, 2014
    Publication date: February 12, 2015
    Inventors: Gabriella GOBBI, Marco MOR, Silvia RIVARA, Franco FRASCHINI, Giorgio TARZIA, Annalida BEDINI, Gilberto SPADONI, Valeria LUCINI
  • Patent number: 8945626
    Abstract: A process for the production of a composition comprising a water-insoluble paracetamol or NSAID which comprises the steps of: a) providing a mixture comprising: i) a water-insoluble paracetamol or NSAID, ii) a water soluble carrier, and iii) a solvent for each of the paracetamol or NSAID and the carrier, and b) spray-drying the mixture to remove the or each solvent and obtain a substantially solvent-free nano-dispersion of the paracetamol or NSAID in the carrier.
    Type: Grant
    Filed: July 13, 2007
    Date of Patent: February 3, 2015
    Inventors: Andrew James Elphick, John Staniforth, Dong Wang, David John Duncalf, Steven Paul Rannard, James Long, Alison Jayne Foster
  • Publication number: 20150024048
    Abstract: Layered pharmaceutical composition suitable for oral use in the treatment of diseases where absorption takes place over a large part of the gastrointestinal tract. The composition comprising A) a solid inner layer comprising i) an active substance, and ii) one or more disintegrants/exploding agents, one of more effervescent agents or a mixture thereof.
    Type: Application
    Filed: July 29, 2014
    Publication date: January 22, 2015
    Inventors: Pernille Hoyrup Hemmingsen, Anders Vagno Pedersen, Daniel Bar-Shalom
  • Publication number: 20140370090
    Abstract: Tablets and other objects are film coated by including in the tablet a film-forming polymer that is activated upon contact with an activating amount of liquid. The film-forming polymer, e.g., a cellulosic ether, is homogeneously mixed with the other ingredients of the tablet, shaped into any desirable form, loaded into a conventional coating apparatus, and sprayed or foamed with an activating amount of fluid, e.g., water, alcohol, etc., and dried. This coating process eliminates potential problems such as spray nozzle clogging, inappropriate coating fluid viscosity, and the inability to properly atomize the coating fluid. This coating process does not impart any appreciable weight or thickness gain to the tablet.
    Type: Application
    Filed: April 16, 2014
    Publication date: December 18, 2014
    Inventors: Paul J. Sheskey, Colin M. Keary
  • Patent number: 8895066
    Abstract: The invention relates to a bilayer composition for the delivery of acetaminophen and tramadol over at least a twelve hour period following initial administration. A single administration of the bilayer composition can provide analgesia starting in less than half an hour to about one hour after initial administration with a duration of at least twelve hours after initial administration.
    Type: Grant
    Filed: October 15, 2008
    Date of Patent: November 25, 2014
    Assignees: Paladin Labs Inc., Paladin Labs Europe Limited, Paladin Labs (Barbados) Inc.
    Inventors: Ali Bichara, Sonia Gervais, Dorothee Le Garrec, Patricia Ouadji, Vinayak Sant, Shiva Gosein, Vincent Lemaire, Samir Taga, Damon Smith
  • Publication number: 20140341988
    Abstract: Pharmaceutical dosage forms, particularly dosage forms in granular form having good palatability and capable of rapidly and completely dispersed in the mouth when orally administered.
    Type: Application
    Filed: May 15, 2014
    Publication date: November 20, 2014
    Applicant: APR APPLIED PHARMA RESEARCH SA
    Inventors: Alberto REINER, Giorgio REINER
  • Publication number: 20140336252
    Abstract: The present invention provides compounds having the structure represented by general formula I, pharmaceutically acceptable salts thereofagonist, preparation methods therefor and a use thereof in the preparation of a medicine for the treatment of nervous system diseases. The compounds or pharmaceutical compositions thereof can be used as the KCNQ potassium channel agonist for treating nervous system diseases. Compared to retigabine, a compound in the prior art, the compound of the present invention have the same or better therapeutic effect, are easier for synthesis and storage, and less prone to oxidate deterioration.
    Type: Application
    Filed: October 23, 2012
    Publication date: November 13, 2014
    Inventors: Fajun Nan, Min Li, Zhaobing Gao, Fei Chen, Yangming Zhang, Pingzheng Zhou, Haining Hu, Haiyan Xu, Sheng Liu
  • Publication number: 20140336205
    Abstract: Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia.
    Type: Application
    Filed: July 23, 2014
    Publication date: November 13, 2014
    Inventors: Changyi Chen, Jian-Ming Lu, Qizhi Yao
  • Patent number: 8877817
    Abstract: The invention concerns a stable aqueous paracetamol solution for use in IV infusion comprising at least one stabilizing-dissolving compound for paracetamol in solution selected from the group consisting of cyclodextrins, at least one stabilizing compound bearing at least one thiol functional group and at least one stabilizing compound selected from the group consisting of Thiamine salts.
    Type: Grant
    Filed: May 18, 2011
    Date of Patent: November 4, 2014
    Inventor: Ioulia Tseti
  • Publication number: 20140322305
    Abstract: Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and/or ketotifen. Embodiments of the composition are administered, for example, by injection, and/or transdermally.
    Type: Application
    Filed: July 10, 2014
    Publication date: October 30, 2014
    Inventor: John Daniel Dobak
  • Patent number: 8865143
    Abstract: A reversely thermo-reversible hydrogel composition comprising a water soluble block copolymer comprising at least two blocks of polyethylene oxide and at least one block of polypropylene oxide, and at least one associative gelling adjuvant having water solubility less than 0.5 g/100 ml, preferably less than 0.3 g/100 ml at 20° C., and being capable of forming water soluble inter-molecular complexes with the water soluble block copolymer in water. The hydrogel composition exhibits improved gelling efficiency, enhanced solubility and/or stability for water sparely soluble and insoluble pharmaceutical agents. The hydrogel compositions are useful in a variety of pharmaceutical and cosmetic products and applications, such as esophageal, otic, vaginal, rectal, ophthalmic, treatments of disorders and imperfections of the skin, and treating and/or preventing alopecia and restoring and/or promoting hair growth.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: October 21, 2014
    Assignee: Broda Technologies Co., Ltd.
    Inventors: Shao Xiang Lu, Jeffrey Lu, Letian Liu
  • Patent number: 8852631
    Abstract: The present invention relates to new acid resistant hard pharmaceutical capsules, a process for their manufacture and use of such capsules particularly but not exclusively for oral administration of pharmaceuticals, veterinary products, food and dietary supplements to humans or animals. The capsules of the invention are obtained by aqueous compositions comprising a water soluble film forming polymer and gellan gum in a mutual weight ratio of 4 to 15 weight parts of gellan gum for 100 weight parts of film forming polymer.
    Type: Grant
    Filed: September 14, 2010
    Date of Patent: October 7, 2014
    Assignee: Capsugel Belgium NV
    Inventors: Dominique Nicolas Cade, Xiongwei David He
  • Publication number: 20140296140
    Abstract: An equipment assembly for preparing, harvesting and collecting particles is disclosed. The assembly comprises a tandem filter system with one or more high pressure filters, one or more low pressure filters and one or more collection vessel. Particles can be prepared, harvested and collected continuously, semi-continuously or in a batch-type operation. A tandem filter system and its method of use are also disclosed. Particles made with the assembly and according the instant methods are also disclosed. The assembly provides improved particle harvesting and collection over other systems and permits continuous particle formation, in particular by dispersion of a solute-containing process fluid within a supercritical anti-solvent.
    Type: Application
    Filed: June 17, 2014
    Publication date: October 2, 2014
    Applicant: CRITITECH, INC.
    Inventors: Greg S. JOHNSON, Bala SUBRAMANIAM, Fenghui Niu
  • Publication number: 20140296197
    Abstract: Combinations comprising (a) a ?2 agonist and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary disease.
    Type: Application
    Filed: June 16, 2014
    Publication date: October 2, 2014
    Inventors: Jordi GRAS ESCARDO, Jesus LLENAS CALVO, Hamish RYDER, Pio ORVIZ DIAZ
  • Publication number: 20140296183
    Abstract: A novel amine compound represented by the following formula (I), which is superior in immunosuppressive action, rejection suppressive action and the like, and shows reduced side effects such as bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or hydrates thereof, or solvate, as well as a pharmaceutical composition containing this compound and a pharmaceutically acceptable carrier. wherein R is a hydrogen atom or P(?O)(OH)2, X is an oxygen atom or a sulfur atom, Y is CH2CH2 or CH?CH, R1 is cyano or alkyl having a carbon number of 1 to 4 and substituted by a halogen atom(s), R2 is alkyl having a carbon number of 1 to 4 and optionally substituted by a hydroxyl group(s) or a halogen atom(s), R3 and R4 may be the same or different and each is a hydrogen atom or alkyl having a carbon number of 1 to 4, and n is 5-8.
    Type: Application
    Filed: June 17, 2014
    Publication date: October 2, 2014
    Inventors: Masatoshi KIUCHI, Kaoru MARUKAWA, Nobutaka KOBAYASHI
  • Publication number: 20140235726
    Abstract: A method of improving cognition in a patient with Down syndrome, which entails administering one or more ?2 adrenergic receptor agonists to the patient in an amount and with a frequency effective to improve cognition of the patient as measured by contextual learning tests
    Type: Application
    Filed: February 12, 2014
    Publication date: August 21, 2014
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Ahmad Salehi, Brian Mediana, Sarah Moghadam, Van Dang, Devsmita Das, Kara Martin
  • Publication number: 20140228391
    Abstract: An anise flavored liquid medication. The liquid medication contains phenylephrine and an anethole analog that is substantially free of aldehyde groups. In one example, the anethole analog can be 1-methoxy-4-n-propylbenzene.
    Type: Application
    Filed: February 13, 2014
    Publication date: August 14, 2014
    Applicant: The Procter & Gamble Company
    Inventors: Allyn Michael Kaufmann, James Carl Grimm, Chelsay Lynn Brewster, Thomas Edward Huetter
  • Publication number: 20140221485
    Abstract: The invention provides novel lipophilic dopamine derivatives with improved stability and physiological half-life. The compounds may be used for organ and tissue preservation during storage and transport, or in the pre-treatment of organ and tissue donor or recipients. Moreover, they may be used as therapeutic agents for the prevention or treatment of ischaemia-related pathological conditions.
    Type: Application
    Filed: August 24, 2012
    Publication date: August 7, 2014
    Inventors: Bernhard Gunther, Bastian Theisingen, Sonja Theisinger
  • Publication number: 20140213617
    Abstract: Provided are alkynyl phenyl derivative compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.
    Type: Application
    Filed: January 23, 2014
    Publication date: July 31, 2014
    Applicant: ACUCELA INC.
    Inventors: Ian Leslie Scott, Vladimir Aleksandrovich Kuksa, Mark W. Orme, Thomas Little, Anna Gall, Jennifer Gage, Feng Hong
  • Patent number: 8791163
    Abstract: Novel melatonin ligands of Formula I: or pharmaceutically acceptable salts thereof wherein: n is 1 or 2; m is 0, 1 or 2; p is 0, 1, 2, 3, 4, 5, 6, 7 or 8; v is 2 or 3; A is aryl or heteroaryl; Z is O, S or NR8; Y is selected from the group consisting of hydrogen, aryl, heteroaryl, C1-C6 alkyl, C3-C6 cycloalkyl, and R is selected from the group consisting of hydrogen, hydroxyl, —OCF3, CF3, C1-C8 alkyl, C1-C8 alkyloxy, C1-C8 alkylthio, halogen and —Z—(CH2)p-A; R1 is selected from the group consisting of C1-C4 alkyl, C3-C6 cycloalkyl, CF3, hydroxy-substituted C1-C4 alkyl, hydroxy-substituted C3-C8 cycloalkyl, and NHR5, wherein R5 is C1-C3 alkyl or C3-C6 cycloalkyl; R2 is selected from the group consisting of: hydrogen, C1-C4 alkyl, C1-C4 alkyloxy, OCF3, CF3, hydroxyl, and halogen; R3 is selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 alkyloxy, OCF3, CF3, hydroxyl, and halogen; R and R3 may be connected together to form an —O—(CH2)v bridge representing with the carbon atoms to which th
    Type: Grant
    Filed: January 12, 2007
    Date of Patent: July 29, 2014
    Assignees: McGill University, Universita Degli Studi di Parma, Universita Degli Studi di Milano, Universita Degli Studi di Urbino
    Inventors: Gabriella Gobbi, Marco Mor, Silvia Rivara, Franco Fraschini, Giorgio Tarzia, Annalida Bedini, Gilberto Spadoni, Valeria Lucini
  • Patent number: 8778402
    Abstract: Dry powder formulations comprising a corticosteroid and a beta2-adrenergic drug in combination are useful for the prevention and/or treatment of inflammatory or obstructive airways diseases.
    Type: Grant
    Filed: January 24, 2013
    Date of Patent: July 15, 2014
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Elisa Monari, Anna Maria Cantarelli, Daniela Cocconi, Irene Pasquali
  • Publication number: 20140154314
    Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in a delayed-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of a pharmaceutical composition comprising an analgesic agent.
    Type: Application
    Filed: February 7, 2014
    Publication date: June 5, 2014
    Applicant: WELLESLEY PHARMACEUTICALS, LLC
    Inventor: David A. DILL
  • Patent number: 8741959
    Abstract: The invention relates to an aqueous pharmaceutical composition, preferably an infusion solution, for parenteral administration which contains paracetamol and has an electrical conductivity of not more than 200 ?S cm?1.
    Type: Grant
    Filed: April 19, 2010
    Date of Patent: June 3, 2014
    Assignee: Fresenius Kabi Deutschland GmbH
    Inventors: David Dasberg, Georg Achleitner, Christiane Aichholzer
  • Publication number: 20140140932
    Abstract: The present disclosure provides functionalized magnetic nanoparticles (MNPs) comprising a functional group that binds to ?-amyloid deposits and/or neurofibrillary tangles. The present disclosure provides compositions comprising the functionalized MNPs, and methods of using the functionalized MNPs in imaging ?-amyloid deposits and neurofibrillary tangles.
    Type: Application
    Filed: April 4, 2012
    Publication date: May 22, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Masoud Akhtari
  • Publication number: 20140141100
    Abstract: Disclosed is a method of treating obesity, reducing weight, preventing weight gain, and/or suppressing appetite in a subject in need thereof by administering topically a pharmaceutical compound having a chemotherapeutic agent to at least a surface of the subject's mouth. The method includes inhibiting taste cell reproduction on the surface of the subject's mouth with the compound and reducing sense of taste, appetite for food in the subject, or a combination thereof.
    Type: Application
    Filed: November 20, 2013
    Publication date: May 22, 2014
    Inventors: Benedict T. Marino, James F. Marino
  • Patent number: 8729132
    Abstract: The present invention relates to an agomelatine hydrobromide hydrate of formula I wherein X is Br, preparation and use thereof, and to pharmaceutical compositions containing it. The agomelatine hydrobromide hydrate obtained through the present method has significant increased solubility than agomelatine, and therefore is more suitable for manufacturing pharmaceutical formulations. In addition, the product enjoys higher stability and purity. Using the present method, product of high purity can be obtained through a simple process, free of any complicated steps.
    Type: Grant
    Filed: March 17, 2011
    Date of Patent: May 20, 2014
    Assignee: Les Laboratoires Servier
    Inventors: Hanbin Shan, Zhedong Yuan, Xueyan Zhu, Peng Zhang, Hongjuan Pan, Xiong Yu
  • Patent number: 8729131
    Abstract: The present invention relates to an agomelatine hydrochloride hydrate of formula I, preparation and use thereof, and to pharmaceutical composition containing it. The agomelatine hydrohalide hydrate obtained through the present method has significant increased solubility than agomelatine, and therefore is more suitable for manufacturing pharmaceutical formulations. In addition, the product enjoys higher stability and purity. Using the present method, product of high purity can be obtained through a simple process, free of any complicated steps. wherein X is Cl.
    Type: Grant
    Filed: March 17, 2011
    Date of Patent: May 20, 2014
    Assignee: Les Laboratoires Servier
    Inventors: Hanbin Shan, Zhedong Yuan, Xueyan Zhu, Peng Zhang, Hongjuan Pan, Xiong Yu
  • Publication number: 20140135302
    Abstract: Methods, compositions, and kits for predicting whether a subject with chronic obstructive pulmonary disease (COPD) or at risk of developing COPD is likely to have progressive COPD are provided. Methods, compositions, and kits for predicting whether lung function is likely to decline in a subject with COPD or at risk for developing COPD are also provided.
    Type: Application
    Filed: November 7, 2013
    Publication date: May 15, 2014
    Applicant: SOMALOGIC, INC.
    Inventors: Malti P. Nikrad, Stuart G. Field, Stephen Alaric Williams, Alex A.E. Stewart, Rachel M. Ostroff, Rosalynn Dianne Gill
  • Patent number: 8722744
    Abstract: A galenical form for the transmucous administration of at least one active ingredient, characterized in that the active ingredient is paracetamol in a stable and complete dissolved state in a hydroalcoholic solution that includes at least 10% by mass of alcohol so as to allow fast absorption of the active ingredient through the mucous membranes of the buccal cavity and/or the oropharynx. A process for production and the uses of the galenical form are also disclosed.
    Type: Grant
    Filed: December 19, 2007
    Date of Patent: May 13, 2014
    Inventors: Philippe Perovitch, Marc Maury
  • Publication number: 20140128415
    Abstract: A excipient drug composition is disclosed. The excipient drug composition may include a vegetable cellulose or a fruit cellulose, an active ingredient and a genetically modified organism free starch. The vegetable cellulose or fruit cellulose may be derived from wood free vegetable pulp and the fruit cellulose is a wood pulp free cellulose. The genetically modified organism free starch may be selected from the group consisting of a genetically modified organism free rice starch, a genetically modified organism free potato starch or a genetically modified organism free pea starch.
    Type: Application
    Filed: January 8, 2014
    Publication date: May 8, 2014
    Inventor: Paul Daniel Yered
  • Patent number: 8716348
    Abstract: Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof, and a steroidal anti-inflammatory agent. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: May 6, 2014
    Assignee: Dey Pharma, L.P.
    Inventors: Partha S. Banerjee, Imtiaz A. Chaudry, Stephen Pham
  • Patent number: 8715701
    Abstract: Protein preparations containing biologically active compounds and the application of the protein preparations obtained, particularly as a component of medicinal and cosmetic preparations as protective substances or in the regeneration of cells and tissues of the human organism, and which can comprise a component of culture media for dermal or hepatic tissues, or for stem cells destined for use in the regeneration of cells and tissues in the human organism.
    Type: Grant
    Filed: November 20, 2007
    Date of Patent: May 6, 2014
    Assignee: Instytut Medycyny Doswiadczalnej I Klinicznej
    Inventors: Andrzej Lipkowski, Anna Grabowska, Katarzyna Kurzepa, Aleksandra Szczucinska